Unprecedented research on antibiotic resistant bacteria

Antibiotic resistant bacteria kill 25,000 people in the EU every year. Developing new antibiotics is crucial, yet highly challenging in a scientific, regulatory and business sense. COMBACTE unites experts across Europe to boost the development of new treatments.

Academia and industry working shoulder to shoulder

The leaders in the field of antimicrobial resistance, from both public and private sectors, are working together as mutual experts. Fostering creative intelligence capable of addressing the challenges faced. Pioneering new ways of designing and implementing efficient clinical trials.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution